JAMA November 12, 2026

Izalontamab Brengitecan in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: The PANKU-Esophagus01 Randomized Clinical Trial

Zhihao Lu, Zhangzhou Huang, Xiangjiao Meng, et al.

Bottom Line

In patients with recurrent or metastatic esophageal squamous cell carcinoma progressing after chemoimmunotherapy, the bispecific antibody-drug conjugate izalontamab brengitecan significantly improved both progression-free and overall survival compared to standard chemotherapy.

Key Findings

1. Izalontamab brengitecan significantly prolonged median overall survival to 9.79 months compared to 7.20 months with standard chemotherapy (hazard ratio, 0.63; 95% CI, 0.48-0.82; P < .001).
2. Median progression-free survival assessed by blinded independent central review was 4.17 months for izalontamab brengitecan versus 1.97 months for the chemotherapy arm (hazard ratio, 0.50; 95% CI, 0.40-0.63; P < .001).
3. Grade 3 or higher treatment-related adverse events were frequent, occurring in 85.1% of patients treated with izalontamab brengitecan (predominantly hematologic) versus 59.3% in the chemotherapy arm.

Study Design

Design
RCT
Open-Label
Sample
497
Patients
Duration
11 mo
Median
Setting
Multicenter, China
Population Adult patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC) whose disease progressed after first-line PD-1/PD-L1 inhibitor plus platinum-containing chemotherapy.
Intervention Izalontamab brengitecan 2.5 mg/kg administered intravenously on days 1 and 8 of every 3-week cycle.
Comparator Physician-selected chemotherapy (irinotecan, paclitaxel, or docetaxel) administered every 3 weeks.
Outcome Dual primary endpoints of progression-free survival (PFS) assessed by blinded independent central review and overall survival (OS).

Study Limitations

• The trial was conducted exclusively in China, which may limit the external validity and generalizability of the findings to a broader, more diverse global patient population.
• Substantial hematologic toxicity (85.1% experiencing Grade 3 or higher treatment-related adverse events) requires diligent monitoring and management in routine clinical practice.
• The data represent a prespecified interim analysis with a relatively short median follow-up of approximately 11 months, requiring further follow-up for mature long-term overall survival outcomes.
• The study's open-label design introduces the potential for performance and detection bias, although this was partially mitigated by using a blinded independent central review for the progression-free survival endpoint.

Clinical Significance

Izalontamab brengitecan, a first-in-class EGFR×HER3 bispecific antibody-drug conjugate, represents a major therapeutic advance for patients with advanced esophageal squamous cell carcinoma. By demonstrating clinically meaningful, dual improvements in progression-free and overall survival in a heavily pretreated population with historically poor outcomes, it establishes a compelling new standard of care for second-line treatment following progression on chemoimmunotherapy.

Historical Context

Advanced esophageal squamous cell carcinoma typically carries a dismal prognosis. With the widespread adoption of upfront PD-1/PD-L1 inhibitors combined with platinum chemotherapy, patients who experience disease progression face a significant unmet clinical need, as subsequent salvage monotherapies offer very poor survival outcomes. Izalontamab brengitecan was developed to simultaneously target EGFR and HER3—receptors heavily implicated in epithelial cancer proliferation—delivering a topoisomerase I inhibitor payload directly to tumor cells. The 2026 PANKU-Esophagus01 trial is a landmark study, marking the first Phase 3 evidence of a bispecific ADC achieving both PFS and OS benefits in esophageal cancer, which drove its regulatory approval.

Guided Discussion

High-yield insights from every perspective

Med Student
Medical Student

How does the mechanism of action of an antibody-drug conjugate (ADC) containing a 'tecan' payload, such as izalontamab brengitecan, differ from traditional systemic chemotherapy in treating esophageal squamous cell carcinoma?

Key Response

ADCs combine target specificity (via the monoclonal antibody) with high cytotoxicity (via the payload). The 'tecan' suffix indicates a topoisomerase I inhibitor payload, which prevents DNA replication by creating single-strand breaks. This targeted delivery minimizes systemic toxicity while concentrating the cytotoxic effect within the tumor microenvironment, distinguishing it from non-specific traditional chemotherapy.

Resident
Resident

In a patient with recurrent esophageal squamous cell carcinoma who has just progressed on first-line fluoropyrimidine, platinum, and pembrolizumab, what are the primary toxicities you must monitor for when initiating an ADC with a topoisomerase I inhibitor payload like izalontamab brengitecan?

Key Response

Topoisomerase I inhibitor-based ADCs commonly cause severe neutropenia, interstitial lung disease (ILD)/pneumonitis, and significant gastrointestinal toxicity like diarrhea. Given the patient's prior immunotherapy, distinguishing ADC-induced pneumonitis from delayed immune-related pneumonitis is a critical management decision.

Fellow
Fellow

The PANKU-Esophagus01 trial utilized a bispecific antibody for its ADC framework. What is the theoretical advantage of a bispecific ADC over a monospecific ADC in overcoming resistance mechanisms in heavily pretreated ESCC, and how might tumor heterogeneity impact its efficacy?

Key Response

Bispecific ADCs target two different tumor antigens simultaneously, which enhances tumor specificity, improves internalization rates, and mitigates resistance caused by the downregulation of a single antigen. However, in highly heterogeneous tumors like ESCC, spatial variation in the expression of both targets could still lead to clonal selection and eventual resistance.

Attending
Attending

Given the significant OS and PFS benefit of izalontamab brengitecan over standard chemotherapy in the second-line setting for ESCC, how should this shift our approach to sequencing therapies, particularly regarding the preservation of performance status and the risk of cumulative overlapping toxicities from first-line chemoimmunotherapy?

Key Response

The introduction of a highly active ADC in the second line means oncologists must be more proactive in switching therapies at the first sign of progression rather than pushing first-line chemoimmunotherapy to the point of clinical deterioration. Careful consideration of cumulative toxicities, especially neuropathy from platinum agents and potential pneumonitis, will dictate how we transition patients to ensure they remain eligible for this life-prolonging second-line agent.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD
PhD

In the PANKU-Esophagus01 trial, how might the choice of the control arm (standard chemotherapy) confound the interpretation of the overall survival benefit if subsequent crossover or post-progression therapies were imbalanced between the two cohorts?

Key Response

If patients in the standard chemotherapy arm did not have access to the experimental ADC or other novel therapies upon progression, the OS benefit might be inflated by the lack of effective third-line options. A rigorous analysis requires evaluating progression-free survival 2 (PFS2) and adjusting for the confounding effects of post-progression treatments using methods like the Rank Preserving Structural Failure Time (RPSFT) model.

Journal Editor
Journal Editor

As a peer reviewer, what specific biomarker analyses must be scrutinized in the supplementary data of the PANKU-Esophagus01 trial to ensure the bispecific ADC's efficacy is not being driven by an unstratified subpopulation with exceptionally high antigen expression?

Key Response

A rigorous editorial review requires verifying whether the randomization was stratified by the expression levels of the dual target antigens. If the survival benefit is entirely driven by the 'target-high' subgroup, a generalized approval for all ESCC patients would be inappropriate, and the trial's claims of broad efficacy must be tempered.

Guideline Committee
Guideline Committee

Should the NCCN and ESMO guidelines for esophageal and esophagogastric junction cancers be updated to recommend izalontamab brengitecan as the preferred category 1, second-line therapy for ESCC post-chemoimmunotherapy over taxanes or irinotecan, and what level of evidence supports this?

Key Response

Current NCCN guidelines typically recommend taxanes (paclitaxel/docetaxel) or irinotecan for second-line ESCC after chemoimmunotherapy failure. Given the randomized, phase 3 nature of the PANKU-Esophagus01 trial demonstrating superiority in both PFS and OS, this provides Level 1 evidence. The committee must weigh the magnitude of OS benefit and toxicity profile against standard chemotherapy to assign a Category 1 recommendation, potentially rendering older single-agent chemotherapies obsolete in this sequence.

Clinical Landscape

Noteworthy Related Trials

2020

KEYNOTE-590 Trial

n = 749 · Lancet

Tested

Pembrolizumab plus chemotherapy

Population

Locally advanced or metastatic esophageal cancer

Comparator

Placebo plus chemotherapy

Endpoint

Overall survival and Progression-free survival

Key result: Pembrolizumab plus chemotherapy significantly improved OS and PFS compared to chemotherapy alone.
2021

ESCORT-1st Trial

n = 596 · JAMA

Tested

Camrelizumab plus chemotherapy

Population

Advanced or metastatic esophageal squamous cell carcinoma

Comparator

Placebo plus chemotherapy

Endpoint

Overall survival and Progression-free survival

Key result: Addition of camrelizumab to chemotherapy significantly prolonged overall survival and progression-free survival.
2022

CheckMate 648 Trial

n = 970 · NEJM

Tested

Nivolumab plus chemotherapy or Nivolumab plus Ipilimumab

Population

Advanced or metastatic esophageal squamous-cell carcinoma

Comparator

Chemotherapy alone

Endpoint

Overall survival and Progression-free survival

Key result: Both nivolumab-based regimens resulted in significantly longer overall survival than chemotherapy alone in patients with advanced ESCC.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis
↑